Omidenepag Isopropyl: uses, dosing, side effects & brands
Omidenepag Isopropyl is a medicine sold in the U.S. under one brand. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
Key facts
- Available as
- Drops
- Sold as
- Omlonti
- Prescription?
- Prescription only
- Generic available?
- Not in our catalog
How omidenepag isopropyl is dosed
From the FDA label for Omlonti (application NDA215092). Other omidenepag isopropyl products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
The recommended dosage is one drop in the affected eye(s) once daily in the evening. ( 2.1 ) 2.1 Recommended Dosage The recommended dosage is one drop in the affected eye(s) once daily in the evening. 2.2 Administration Instructions Gently shake the bottle prior to administration. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart. Contact lenses should be removed prior to the administration of Omlonti, and may be reinserted 15 minutes after administration [see Patient Counseling Information (17) ].
Omidenepag Isopropyl side effects
The following clinically significant adverse reactions are described elsewhere in the labeling: Pigmentation [see Warnings and Precautions (5.1) ] Eyelash Changes [see Warnings and Precautions (5.2) ] Ocular Inflammation [see Warnings and Precautions (5.3) ] Macular Edema [see Warnings and Precautions (5.4) ] The most common adverse reactions with incidence ≥ 1% are conjunctival hyperemia (9%), photophobia (5%), vision blurred (4%), dry eye (3%), instillation site pain (3%), eye pain (2%), ocular hyperemia (2%), punctate keratitis (2%), headache (2%), eye irritation (1%), and visual impairment (1%). ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Ocuvex at 1-877-622-9326 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described below reflect exposure to Omlonti in 600 patients for up to 3 months . The most common adverse reactions with incidence ≥ 1% are conjunctival hyperemia (9%), photophobia (5%), vision blurred (4%), dry eye (3%), instillation site pain (3%), eye pain (2%), ocular hyperemia (2%), punctate keratitis (2%), headache (2%), eye irritation (1%), and…
Who shouldn’t take omidenepag isopropyl
None. None ( 4 )
Every omidenepag isopropyl product we track (1)
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
Only one: Omlonti.
What people report to the FDA about omidenepag isopropyl
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 53 reports naming omidenepag isopropyl, and the FDA flagged 98% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- cataract15 reports
- intercepted product prescribing error5 reports
- anaphylactic reaction4 reports
- contraindicated product administered4 reports
- cystoid macular oedema4 reports
- macular oedema4 reports
- intraocular pressure increased3 reports
- ocular hyperaemia3 reports
Read these as a signal, not a rate. A report does not mean omidenepag isopropyl caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label section above.
Source: openFDA drug/event (FAERS), retrieved July 25, 2026.
Related calculators
Frequently asked questions
What is omidenepag isopropyl?
Omlonti (omidenepag isopropyl ophthalmic solution) 0.002%, contains the prodrug form of the active omidenepag, a relatively selective prostaglandin EP2 receptor agonist with ocular hypotensive activity. Omidenepag isopropyl is a white to light brown crystal or crystalline powder and practically insoluble in water.
Can you take omidenepag isopropyl with other medicines?
It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run omidenepag isopropyl against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What forms does omidenepag isopropyl come in?
Across the brands we track, omidenepag isopropyl is currently marketed as drops, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.
Is there a generic omidenepag isopropyl?
We do not currently list a generic-labelled omidenepag isopropyl product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.
Cite this page
- APA
- pharmaranks. (2026, July 24). Omidenepag Isopropyl: uses, dosing, side effects & brands. https://pharmaranks.com/drugs/omidenepag-isopropyl
- MLA
- “Omidenepag Isopropyl: uses, dosing, side effects & brands.” pharmaranks, 24 July 2026, https://pharmaranks.com/drugs/omidenepag-isopropyl.
We summarise public FDA and NIH sources — for a clinical claim, cite the primary source we link to as well.
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
Read the full FDA label for omidenepag isopropyl on DailyMed (NIH) ↗.